<DOC>
	<DOCNO>NCT02505191</DOCNO>
	<brief_summary>A pilot phase I , randomise , open mono-center , two parallel group clinical trial investigate pharmacokinetics prolonged-release formulation comparison immediate-release formulation St. John 's wort extract Ze 117 healthy male volunteer fast condition .</brief_summary>
	<brief_title>Pilot Pharmacokinetic Study Prolonged-release Formulation St. John 's Wort Extract Ze 117</brief_title>
	<detailed_description />
	<criteria>Caucasian male volunteer Physically mentally healthy judged mean medical standard laboratory examination BMI 19 29 kg/m2 , inclusively Weight exceed 90 kg Nonsmokers ( confirm urine cotinine test ) Informed cConsent document signature Known suspect hypersensitivity ingredient investigational medicinal product Any clinically significant illness clinically significant surgery within 1 year prior administration study medication Any surgical medical condition might interfere absorption , distribution , metabolism excretion drug Any clinically significant abnormality abnormal laboratory test result , judge investigator find medical screening Positive test hepatitis B , hepatitis C HIV screening ( HIV antibody , Hepatitis B ( HBsAg ) , Hepatitis C ( HCV ) ECG abnormality ( clinical significant ) vital sign abnormality ( systolic blood pressure low 90 145 mmHg , diastolic blood pressure low 60 95 mmHg , heart rate less 45 100bpm ) screen History asthma obstructive pulmonary disease ( e.g.COPD ) Known photohypersensitivity . Presents history alcohol dependence within last year ( &gt; 40 g ethanol/d 10 unit per week ( 1unit=150 ml wine 360 ml beer 45 ml alcohol 45 % ) ) History drug dependence positive result drug screen Concomitant participation another clinical trial within 4 week prior plan first drug administration . Donation blood blood product within 30 day prior plan first drug administration . Treatment medication topical drug systemic action use past 4 week , prior plan first drug administration , 6 time halflife respective drug , whatever long ( exclude single use paracetamol ibuprofen 24 hour prior plan first drug administration ) . Suspected inability , e.g . language problem , know suspected noncompliance , e.g . nonwillingness fulfil dietary restriction Difficulty swallow study medication Enrolment investigator , his/her family member , employee dependent person Any reason , opinion Investigator , would prevent subject participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>